[Systemic therapies for advanced thyroid cancer - an update].
In: Deutsche medizinische Wochenschrift (1946), Jg. 148 (2023-11-01), Heft 22, S. 1412-1418
academicJournal
Zugriff:
Based on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. Only recently, based on the randomized trial COSMIC-311, Cabozantinib has been approved as a second-line treatment option in advanced rrDTC. As first in-label selective RET-Inhibitor, Selpercatinib showed promising efficacy in advanced MTC (first line) with RET mutations and rrDTC (second line) with RET fusions along with fewer side effects. Changes and new approaches for the treatment of ATC have been summarised in the current ATA guidelines.
Competing Interests: Tim Brandenburg erklärt finanzielle Verbindungen zu Eisai (Vortragshonorare & Advisory Boards, zu Lilly (Vortragshonorare, Advisory Boards & Consultancy sowie zu Bayer Pharma (Advisory Boards). Yara Maria Machlah: keine. Dagmar Führer gibt Vortragshonorare und Beratertätigkeiten für Eisai, Lilly und Roche sowie Teilnahme an klinischen Studien von Novartis an.
(Thieme. All rights reserved.)
Titel: |
[Systemic therapies for advanced thyroid cancer - an update].
|
---|---|
Autor/in / Beteiligte Person: | Brandenburg, T ; Machlah, YM ; Führer-Sakel, D |
Zeitschrift: | Deutsche medizinische Wochenschrift (1946), Jg. 148 (2023-11-01), Heft 22, S. 1412-1418 |
Veröffentlichung: | Stuttgart [etc.] : G. Thieme, 1946-, 2023 |
Medientyp: | academicJournal |
ISSN: | 1439-4413 (electronic) |
DOI: | 10.1055/a-1951-2902 |
Schlagwort: |
|
Sonstiges: |
|